AZN, Daiichi's Enhertu Gets FDA Nod for Two New Breast Cancer Settings
AstraZeneca and Daiichi win FDA approval for Enhertu in two new HER2-positive early breast cancer treatment settings.
Open original sourceLoading market dashboard
AstraZeneca and Daiichi win FDA approval for Enhertu in two new HER2-positive early breast cancer treatment settings.
Open original source